COMP <GO>
XTLB vs NCNA // EV/EBITDA & P/E VALUATION
XTL Biopharmaceuticals Ltd. (NASDAQ) VS. NuCana plc (NASDAQ) • 15-METRIC TALLY: XTLB 0
— NCNA 2
■ METRIC PARITY
LAST: $1.76 (-12.44%) • MKT CAP: $4.3M
valuation
—
LAST: $1.04 (-3.26%) • MKT CAP: $4.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XTLB VS. NCNA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XTLB | NCNA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.8 | 40.3 | -6.48 | NCNA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.3M | $4.3M | -$3.3K | NCNA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XTLB REV | NCNA REV | XTLB GROSS % | NCNA GROSS % | XTLB FCF | NCNA FCF |
|---|---|---|---|---|---|---|
| INSPECT INDIVIDUAL XBRL MODELS AT XTLB FA <GO> AND NCNA FA <GO>. | ||||||
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XTLB // BETA —
NCNA // BETA —